| HS Code | 391335 |
| Product Name | Nipagin Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions |
| Chemical Name | Methyl 4-hydroxybenzoate |
| Synonym | Methylparaben |
| Cas Number | 99-76-3 |
| Molecular Formula | C8H8O3 |
| Molecular Weight | 152.15 g/mol |
| Appearance | White or almost white crystalline powder |
| Solubility | Freely soluble in ethanol and methanol; slightly soluble in water, ether, and fixed oils |
| Melting Point | 125°C to 128°C |
| Assay | 98.0% to 102.0% on dried basis |
| Function | Antimicrobial preservative and antifungal agent |
| Grade | Veterinary Grade API |
| Applications | Used as a preservative in veterinary tablets, injections, capsules, powders, granules, premixes, and solutions |
| Storage Conditions | Store in a well-closed container, protected from light and moisture, at controlled room temperature |
| Packaging | Sealed, inert, and moisture-proof pharmaceutical-grade containers |
As an accredited Nipagin Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Nipagin Veterinary Grade API is supplied in 25 kg net weight, packaged in double polyethylene-lined fiber drums for safe, stable storage. |
| Container Loading (20′ FCL) | 20′ FCL: Palletized Nipagin veterinary API, secured with dunnage, loaded into clean, dry, ventilated container; prevents contamination and ensures safe transport. |
| Shipping | Nipagin Veterinary Grade API is shipped in sealed, inert, moisture-protected containers with tamper-evident seals, ensuring purity and stability. Packaging is labeled for pharmaceutical use and suitable for formulations in tablets, injections, capsules, powders, granules, premix, and solutions. Standard transport complies with international safety regulations, with tracking provided. |
| Storage | Store Nipagin (Methylparaben) Veterinary Grade API in a tightly sealed, original container in a cool, dry, well-ventilated area. Protect from direct sunlight, moisture, and excessive heat. Avoid contact with strong oxidizers. Ensure container remains closed when not in use to prevent contamination and maintain stability for tablet, injection, capsule, powder, granule, premix, and solution formulations. |
| Shelf Life | Shelf life: 36 months when stored in original, tightly sealed containers below 25°C, protected from light and moisture. |
Preservation of a multi-dose injectable line for cattle and swine begins with the aqueous phase of the formulation. Methyl 4-hydroxybenzoate is dissolved in Water for Injection at 70–80°C under low-shear agitation. The solubility limit of the compound is approximately 1 g in 400 mL of water at 25°C; therefore, target concentrations above 0.18% w/v require a heated compounding hold step or a co-solvent system such as propylene glycol at 10–20% v/v. Transfer lines from the compounding vessel to the storage tank must be jacketed or traced because temperatures below 65°C produce crystalline precipitation. The clear solution is cooled to 40°C before addition of heat-labile B vitamins or other actives.
Target preservative concentrations for multi-dose injectables are generally in the range of 0.10–0.20% w/v, but the actual free concentration depends on partitioning into rubber closures and oil-phase components. Formulators using bromobutyl plungers must confirm preservative recovery after 30 days of inverted storage at 40°C/75% RH according to ICH stability protocols. Compendial guidance requires antimicrobial effectiveness testing under USP <51> or Ph. Eur. 5.1.3. Terminal steam sterilisation at 121°C for 15 min may reduce methyl 4-hydroxybenzoate content by less than 5% when the pH is maintained at 4.0–5.5; batch records from aseptic lines show that pH excursions above 7.0 produce measurable p-hydroxybenzoic acid peaks. Uncoated rubber stoppers with high aromatic naphthenic oil content are a known incompatibility because methylparaben partitions into the closure and fails the 28-day microbial challenge criteria.
The fill line should use 0.22 µm membrane filtration prior to filling, and the storage tank should be blanketed with nitrogen if the solution is held longer than 8 h. Avoid direct contact with amine-based buffering agents at elevated pH during the cooling phase because ester hydrolysis accelerates above pH 7.5. Terminal products in this category include 100 mL and 250 mL multi-dose vitamin B-complex and selenium supplement injections. These products require preserved aqueous vehicles meeting USP <1111> category 1 or Ph. Eur. 5.1.3 acceptance criteria for parenteral preparations.
Oral drench solutions for sheep and cattle often contain carbonate or bicarbonate buffers that raise the vehicle pH above 8.0. Methyl 4-hydroxybenzoate undergoes alkaline hydrolysis of the ester bond under these conditions, forming p-hydroxybenzoic acid and methanol. Preservative challenge data from a high-pH oral electrolyte line indicate that the free ester concentration falls below the minimum inhibitory concentration after 14 days at 30°C when the initial pH exceeds 7.5. For this reason, oral drench formulations preserved with Nipagin Veterinary Grade methyl 4-hydroxybenzoate should be buffered to pH 4.0–6.0 using citrate or phosphate systems.
A typical oral solution formula contains 0.05–0.15% w/v methyl 4-hydroxybenzoate in a vehicle containing 10–30% v/v propylene glycol, 0.1–0.3% w/v sodium carboxymethylcellulose, and 0.05–0.15% w/v citric acid. The paraben is pre-dissolved in the glycol phase under agitation at 60–70°C before being drawn into the purified water phase. Filling lines for 500 mL and 1 L HDPE bottles use 20–50 µm in-line basket filters; filter clogging occurs when the concentrate is cooled too rapidly below 40°C and paraben recrystallises. Storage tanks should maintain gentle recirculation during the holding period to prevent localised concentration gradients.
Terminal products include oral vitamin A/D₃/E drenches and coccidiosis treatment suspensions. These non-sterile liquids are tested for microbiological quality according to USP <1111> and for preservative efficacy according to USP <51> category 3. The critical processing conflict is that polysorbate 80, often added at 0.2–0.5% w/v as a wetting agent, reduces free paraben concentration through micellar partitioning. Batch adjustment requires increasing the preservative level by 10–20% when polysorbate concentrations exceed 0.3% w/v, but the maximum paraben concentration should remain below 0.20% w/v to avoid precipitation at 5°C warehouse storage conditions.
| Dosage form | Methyl 4-hydroxybenzoate loading | Solvent system | Processing temperature | Critical boundary | Compendial reference |
|---|---|---|---|---|---|
| Multi-dose injectable | 0.10–0.20% w/v | Water for Injection, propylene glycol 10–20% v/v | 70–80°C dissolution, fill at 20–25°C | pH 4.0–5.5; rubber closure partitioning | USP <51>, Ph. Eur. 5.1.3 |
| Oral drench | 0.05–0.15% w/v | Propylene glycol 10–30% v/v, water | 60–70°C pre-dissolution | pH ≤ 6.0; polysorbate 80 ≤ 0.3% w/v | USP <1111>, USP <51> |
| Chewable tablet granulation | 0.05–0.10% w/w dry granulate | Purified water, PVP K 30 | 70–80°C dissolution, spray at 30–40°C | Residual moisture ≤ 2.0% w/w | 21 CFR 211.113 |
| Softgel fill | 0.05–0.15% w/w fill mass | Propylene glycol or glycerol ≥ 10% w/w | 60–70°C dissolution, fill at 40–50°C | Gelatin shell moisture 30–40% w/w | ICH Q1A(R2) |
| Reconstitutable powder | 0.05–0.10% w/v after reconstitution | Dry blend with dextrose monohydrate | 20–25°C dry blending | ≥ 90% through 250 µm sieve; RH ≤ 40% | USP <51> category 3 |
| Lipid-coated granules | 0.05–0.15% w/w granule mass | Hydrogenated vegetable oil, lecithin, glyceryl monostearate | 60–70°C lipid melt, bed at 40–55°C | Spray line temperature ≥ 55°C | ICH Q1A(R2) |
| Molasses premix | 0.05–0.20% w/w carrier | Propylene glycol | 50–60°C spray | Premix moisture ≤ 10.0% w/w; RSD ≤ 5.0% | Regional feed regulations |
During wet granulation of meat-flavoured chewable tablets for dogs, the aqueous binder phase may stand for 24–48 h before spraying. Microbial proliferation in starch-based binders produces biofilm slugs that block 0.8 mm spray nozzles on top-spray fluidised bed units. Methyl 4-hydroxybenzoate is added at 0.05–0.10% w/w relative to the total dry granulate weight, dissolved in the heated binder solution at 70–80°C before adding polyvinylpyrrolidone K 30. A production-scale high-shear granulator with a 600 L bowl and 15–20% binder addition rate runs at an impeller speed of 100–150 rpm and a chopper speed of 1,000–1,500 rpm. The preserved binder solution must be cooled to 30–40°C before spraying to prevent thermal degradation of heat-sensitive palatants.
Residual moisture after drying in a fluidised bed at an inlet temperature of 60–70°C should be below 2.0% w/w to reduce free water available for paraben hydrolysis. The terminal product is a chewable tablet containing 0.02–0.05% w/w methyl 4-hydroxybenzoate in the finished tablet core, which is below any effective preservative level in the dry matrix but represents carry-over from preserved granulation fluid. Tablets are film-coated with an aqueous coating dispersion that may also contain 0.05–0.10% w/w methyl 4-hydroxybenzoate to prevent yeast growth in the coating pan sump. Swab samples from coating pan drains after 16 h of continuous operation show yeast counts below 10 CFU/mL when the coating dispersion is preserved.
Compliance for tablet preservatives is less prescribed than for liquids; however, 21 CFR 211.113 requires written procedures to prevent microbiological contamination of non-sterile drug products. The main processing conflict is that methyl 4-hydroxybenzoate can be lost through volatilisation if the drying inlet air temperature exceeds 70°C for more than 30 min. This is an operational boundary rather than a thermal degradation limit because the melting point of methyl 4-hydroxybenzoate is approximately 125–128°C.
For liquid-filled hard or soft gelatin capsules intended for companion animal deworming programs, methyl 4-hydroxybenzoate is incorporated into the fill matrix rather than the shell. The fill matrix often contains soybean oil or medium-chain triglycerides; methyl 4-hydroxybenzoate has low solubility in these oils and must first be dissolved in propylene glycol or glycerol at 60–70°C. A 1000 mg softgel fill mass may contain 0.05–0.15% w/w methyl 4-hydroxybenzoate, with the glycol mass fraction maintained above 10% w/w to hold the paraben in solution after cooling to 25°C. Direct addition of solid paraben powder to the oil phase causes persistent crystal formation on the fill holding tank sidewalls.
Migration of methyl 4-hydroxybenzoate into the gelatin shell can reduce the fill concentration over time. Paraben migration into the shell plasticises the gel ribbon and may delay sealing. Encapsulation lines using rotary die processes set ribbon thickness at 0.8–1.0 mm and sealing temperature at 40–50°C. In-process checks of shell moisture at 30–40% w/w are required because a wetter shell increases paraben migration. Published data for specific paraben migration kinetics in animal health softgels are limited; packaging stability studies according to ICH Q1A(R2) at 25°C/60% RH and 40°C/75% RH are used to set the fill preservative level.
Terminal products include paste-filled worming capsules and oil-soluble vitamin capsules for breeding stock. The fill mass is usually preserved at 0.1% w/w, and the finished capsules are tested for hydrolytic degradation of the paraben using an HPLC method with UV detection at 254 nm. A processing boundary is to avoid direct contact between solid methyl 4-hydroxybenzoate crystals and gelatin ribbon dust because the powder adheres to the sealing seam and causes leak test failures. The filling line should be maintained at 20–25°C and 40–50% RH; lower humidity increases static charge on the gelatin ribbon and can disturb fill weight uniformity.
A reconstitutable oral powder for poultry drinking water is blended in a 500 kg ribbon mixer with a fill level of 70–75% and a mixing time of 15–20 min. Methyl 4-hydroxybenzoate is first triturated with dextrose monohydrate in a 1:9 ratio through a 500 µm stainless-steel screen to break agglomerates. The preservative concentration in the finished dry powder is calculated to yield 0.05–0.10% w/v in the final reconstituted solution. Geometric dilution through at least three stages prevents localised paraben-rich zones that would produce turbid reconstitution.
Particle size distribution of the paraben fraction is critical because large crystals dissolve slowly in cold drinking water. A typical specification requires not less than 90% through a 250 µm sieve and not less than 50% through a 150 µm sieve. The dry powder is filled into laminated foil sachets at relative humidity below 40% RH and 20–25°C. If the powder contains effervescent components such as citric acid and sodium bicarbonate, the paraben must not be pre-dissolved in water during manufacture; instead, it is mixed into the dry acid granule phase to avoid premature effervescence.
The reconstituted solution is typically used within 24 h in poultry nipple drinker lines. Preservative challenge testing according to USP <51> category 3 or Ph. Eur. 5.1.3 is conducted on the reconstituted liquid at the lowest intended dilution. A reconstituted solution at pH 6.5–7.0 can maintain bacterial and fungal counts within compendial limits for 7 days under ambient poultry house temperatures of 25–30°C, provided the solution is not exposed to direct sunlight. Terminal products include water-soluble vitamin and electrolyte powders for broiler and layer flocks.
Oral granules for top-dress application in swine or horses are manufactured by spraying a molten lipid binder containing methyl 4-hydroxybenzoate onto a fluidised bed of carrier particles. The binder system may be composed of hydrogenated vegetable oil, lecithin, and glyceryl monostearate heated to 60–70°C. Methyl 4-hydroxybenzoate dissolves in the molten lipid phase at 0.05–0.15% w/w of the total granule mass. The top-spray fluidised bed uses an inlet air temperature of 40–55°C because lipid solidification occurs below 35°C and nozzle blockage occurs if the spray line temperature drops by more than 5°C.
Granules are discharged after the product bed temperature reaches 25–30°C and are screened through a 1.25–2.00 mm sieve. Oversized material passing through a cone mill with a 1.5 mm screen at 500–800 rpm is recycled to the fluidised bed. The lipid coating retards moisture ingress and reduces paraben migration into the carrier. Prolonged storage above 30°C may cause lipid bloom and uneven preservative distribution. Accelerated stability testing at 40°C/75% RH for 6 months is used to verify content uniformity, because HPLC analysis of the paraben in lipid-coated granules often shows a relative standard deviation below 2.0% after 6 months when the coating is intact.
Terminal products include medicated granules for feed top-dress. The preservation objective in dry granules is not microbial control of the finished dry product but preservation of the lipid binder during manufacturing. A processing boundary is that the paraben must not be added directly to the hot lipid phase at temperatures above 80°C because thermal discoloration appears. Published data for specific paraben stability in this configuration are limited; manufacturers rely on internal qualification batches following ICH Q1A(R2) rather than on published compendial monographs.
In medicated feed premixes intended for incorporation at 0.5–2.0% into pig or poultry feed, molasses-coated carriers present a high water activity environment during storage. Methyl 4-hydroxybenzoate is sprayed onto the carrier at 0.05–0.20% w/w as a solution in propylene glycol at 50–60°C. The spray is applied through a twin-fluid nozzle at 0.5–1.0 bar atomising air pressure onto a horizontal paddle mixer running at 20–30 rpm. Homogeneity is checked by sampling 10 points per batch and analysing paraben by HPLC; acceptance criteria require a relative standard deviation of not more than 5.0%.
The preserved premix is then blended with calcium carbonate, dicalcium phosphate, and trace minerals. The presence of free moisture in molasses fractions above 12.0% w/w reduces the preservative effect because methyl 4-hydroxybenzoate partitions into the aqueous phase and is metabolised by certain fungal species. Storage trials in 25 kg woven polypropylene bags with polyethylene liners show that the paraben level remains above 90% of label claim for 12 months at 25°C/60% RH when the premix moisture is below 10.0% w/w. If the premix is stored in silos at above 30°C, caking and microbial pockets may occur.
Terminal products include vitamin-trace mineral premixes for swine gestation and lactation rations. Regulatory acceptance of methyl 4-hydroxybenzoate in feed premixes varies by jurisdiction; in some markets, feed preservative regulations are separate from veterinary pharmaceutical excipient regulations. Published data for this specific configuration is limited, and registration dossiers often rely on supplier master files rather than public reference standards. The manufacturing line must avoid contamination of subsequent non-preserved batches because methyl 4-hydroxybenzoate residues in the spray line are difficult to remove and can carry over at 0.001–0.005% w/w without a validated cleaning procedure.
Competitive Nipagin Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8615365186327 or mail to admin@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8615365186327
Email: admin@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
Nipagin Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is the pharmaceutical designation for methyl 4-hydroxybenzoate, CAS 99-76-3, molecular formula C8H8O3, relative molecular mass 152.15 g/mol. The product is supplied as a white, crystalline powder or colourless crystalline needles with a melting range of 125–128 °C. Within the Nipagin series, the methyl ester is designated Nipagin M, distinguishing it from Nipagin A (ethyl 4-hydroxybenzoate) and Nipasol M (propyl 4-hydroxybenzoate). The veterinary API grade is not identical to technical-grade methylparaben; release is controlled by pharmacopoeial monograph methods, residual solvent limits according to VICH GL18, and active substance manufacturing requirements under EU GMP Part II. In veterinary dosage forms, methylparaben functions as an antimicrobial preservative rather than a therapeutically active ingredient, and its suitability must be demonstrated in the finished formulation rather than being assumed from the API assay alone.
Release of the veterinary API is controlled against two overlapping pharmacopoeial frameworks. The following table lists representative release limits based on Ph. Eur. and USP-NF methylparaben monographs; individual certificates of analysis may use either system, but the same chromatographic related-substance procedure is typically employed for batch release.
| Attribute | Limits | Reference method |
|---|---|---|
| Appearance | White crystalline powder or colourless crystals | Visual |
| Identification | IR spectrum concordant with Ph. Eur. reference; melting range 125–128 °C | Ph. Eur. 2.2.24, 2.2.14 |
| Assay, dried basis | 98.0–102.0% (USP-NF) or 99.0–100.5% (Ph. Eur.) | HPLC, Ph. Eur. 2.2.29 |
| Related substances: single unknown | ≤ 0.2% | HPLC, Ph. Eur. 2.2.29 |
| Related substances: total | ≤ 0.5% | HPLC, Ph. Eur. 2.2.29 |
| Sulphated ash | ≤ 0.1% | Ph. Eur. 2.4.14 |
| Loss on drying | ≤ 0.5% | Ph. Eur. 2.2.32 |
| Residual solvents | Class 3 solvents within VICH GL18 / Ph. Eur. 5.4 limits | Headspace gas chromatography |
The assay difference between the USP-NF and Ph. Eur. limits reflects different historical acceptance criteria rather than a change in typical batch purity; commercial batches frequently release above 99.5%. For veterinary injection applications, the formulator should request a batch-specific certificate showing chromatographic purity, residual solvents and, where relevant, microbial and endotoxin data because the non-sterile API is not automatically pyrogen-free.
Direct compression and dry granulation of veterinary tablets and powders containing Nipagin M require attention to crystal habit. Methyl 4-hydroxybenzoate forms needle-like crystals that can segregate during high-speed tablet compression; co-milling with a portion of the lactose or mannitol diluent through a 0.5 mm screen is used to reduce content-uniformity failures. In wet granulation, the compound is incorporated into the dry powder mixture before addition of the granulating solution, or it is pre-dissolved in a non-aqueous granulating solvent. Because the final tablet core has water activity below 0.6, methylparaben in the dry tablet is not required for preservation of the finished solid core; its function is process preservation in the aqueous granulating liquid or coating dispersion.
Alkaline conditions above pH 8 promote ester hydrolysis to p-hydroxybenzoic acid, with the rate increasing as the pH approaches 10. This reduces both preservative activity and assay. Methylparaben has a reported pKa of 8.17 at 25 °C; the undissociated acid is the membrane-active species, so ionisation above the pKa lowers antimicrobial effectiveness. Injectable solutions formulated above pH 7.5 are therefore evaluated for assay loss after terminal sterilisation. Published stability data indicate that autoclaving at 121 °C for 15 min under acidic conditions is generally compatible, while alkaline autoclaving can produce unacceptable related-substance increases; for alkaline formulations the sodium salt or an alternative preservative system is normally evaluated rather than increasing the methylparaben load.
Another critical limit is interaction with nonionic surfactants. Polysorbate 80 and Cremophor-type vehicles form micelles that sequester methylparaben and reduce free preservative concentration in water. The result is a false assurance if total concentration is measured; preservative efficacy can fail despite a total methylparaben content of 0.1–0.2% w/v. The finished multidose injection should be challenged after compounding by Ph. Eur. 5.1.3 or USP <51> antimicrobial effectiveness testing, and the free preservative concentration may be confirmed by ultrafiltration or equilibrium dialysis.
In high-lipid vehicles such as oil-based injections, topical ointments and certain feed premix carriers, selection between methylparaben and propylparaben is governed by partition behaviour. The lower log P and higher water solubility of Nipagin M favour the aqueous phase, while Nipasol M remains partitioned in lipid domains and may be depleted from water. A combination of the two esters is often used to cover both aqueous and lipid phases in emulsions. The following table compares the methyl and propyl esters.
| Parameter | Nipagin M (methyl 4-hydroxybenzoate) | Nipasol M (propyl 4-hydroxybenzoate) |
|---|---|---|
| Aqueous solubility at 25 °C | 2.5 g/L | 0.4 g/L |
| Octanol-water log P | 1.96 | 3.04 |
| Typical aqueous multidose injection preservative level | 0.05–0.2% w/v alone or in combination | 0.01–0.05% w/v in combination because of lower solubility |
| Activity profile | Stronger activity against moulds and Gram-positive bacteria; weaker against Gram-negative organisms | Higher retention in lipid bilayers; often combined with methylparaben for broader Gram-negative coverage |
For oral solutions and premix reconstitution fluids, methylparaben alone may be sufficient at 0.05–0.2% w/v when the pH is maintained below 7.5 and the surfactant level is low. If the formulation contains high concentrations of polysorbate or lipid emulsifiers, a partition-adjusted combination of methylparaben and propylparaben is tested rather than assuming preservative efficacy from literature concentration ranges.
Nipagin A (ethyl 4-hydroxybenzoate) occupies an intermediate position in solubility and log P; it is used less frequently in aqueous veterinary injections because methylparaben provides higher aqueous solubility at similar fungal coverage. The sodium methylparaben derivative is the cold-water-soluble form, but it raises the pH of the vehicle and can precipitate as the free acid after dilution into acidic buffer systems; Nipagin M is therefore selected when neutral pH and direct solubility in organic solvents are required.
The antimicrobial activity of Nipagin M is attributable primarily to the undissociated acid fraction, which disrupts cytoplasmic membrane and proton transport in susceptible microorganisms. The compound has strongest activity against moulds and Gram-positive bacteria, lower activity against Gram-negative bacteria, and minimal activity against bacterial spores. For multidose veterinary injections, this spectrum is a reason for combination use with propylparaben or with a low level of EDTA; neither methylparaben nor propylparaben alone can be assumed to give the required reduction in Pseudomonas aeruginosa challenge organisms under Ph. Eur. 5.1.3 criteria at low concentrations.
Because the free acid concentration controls activity, the formulation pH, buffer species and co-solvents are more important than the nominal API load. In a solution buffered at pH 7.0, the undissociated fraction is above 90%, whereas at pH 8.17 only 50% is present as the active acid. Co-solvents such as propylene glycol and ethanol can alter the pKa and free concentration; therefore antimicrobial effectiveness testing is required for the final container-closure system, not merely for the bulk solution.
The dosage-form examples listed in the product designation do not place identical demands on the preservative. For tablets, capsules, powders and granules, the preservative is used during wet processing rather than to protect the final dry dosage form; finished solid cores with water activity below 0.6 are not susceptible to microbial multiplication under routine storage. In aqueous film-coating dispersions, Nipagin M is dissolved in the organic phase or added as a dispersion to protect the coating liquid during 8–24 h processing windows.
For oral liquids, aqueous suspensions and reconstituted powders, methylparaben is used at 0.05–0.2% w/v; for semi-solid preparations, the upper range may be required because of partition into oil-phase components. Because the aqueous solubility of the free acid is 2.5 g/L at 25 °C, solutions above 0.2% w/v are normally prepared by heating to 50–60 °C or by pre-dissolving in ethanol or propylene glycol. The sodium salt is used for cold preparation; however, it raises pH and can precipitate as the free acid in acidic buffers. For multidose injections, a typical preservative system includes methylparaben 0.1% w/v plus propylparaben 0.01% w/v, but this combination must be validated in the specific formulation. Nipagin M is not a sterilant and is not a substitute for terminal sterilisation or aseptic processing of parenteral products; it only suppresses microbial growth after opening.
In medicated feed premixes, the function of Nipagin M depends on water activity and storage humidity. Dry premixes with water activity below 0.6 and closed packaging rarely require a preservative for antimicrobial protection of the final premix; published data for this specific low-moisture configuration are limited. When the premix contains hygroscopic carriers or is exposed to repeated air exchange at relative humidity above 60% RH, methylparaben can be incorporated at the granulation stage to preserve residual water in the carrier; however, the inclusion level must be justified by stability and challenge data rather than extrapolated from oral liquid concentrations.
Incompatibilities include nonionic surfactants, strong bases, and strong oxidising agents. Nonionic micelles reduce free methylparaben; alkaline conditions hydrolyse the ester to p-hydroxybenzoic acid; strong oxidising agents can produce coloured degradation products. Material should be stored in well-closed polyethylene-lined containers at controlled room temperature, protected from light. Moisture uptake above 60% RH can reduce flowability and increase caking in direct compression blends; opened containers should be re-sealed immediately after weighing and not held in humid processing areas for extended periods.
